Publications by authors named "Juul M P A Van den Reek"
Frailty and functional dependency in a multicenter cohort of older adults with psoriasis: Prevalence and extent of and implications for psoriasis management.
J Am Acad Dermatol
December 2024
Article Synopsis
- Biologics are effective treatments for psoriasis, and this study focuses on patients who have used the same biologic for 10 years or more, referred to as "ultra-long users."
- In the BioCAPTURE cohort, 30.5% of eligible patients reached this ultra-long treatment duration, with ustekinumab being the most common biologic among them.
- The study found that many ultra-long users had comorbidities, required dose adjustments, and achieved relatively low complete clearance rates of psoriasis, but still showed a high retention rate on the treatment for over 15 years.
Importance: Treating patients with chronic urticaria using omalizumab has been shown to be safe and effective in randomized clinical trials. Multinational studies on long-term omalizumab performance in chronic urticaria in clinical practice settings are lacking, especially on drug survival. Drug survival, which refers to the length of time that patients are treated with a specific drug, is a comprehensive outcome covering effectiveness, safety, and patient and physician preferences.
View Article and Find Full Text PDFArticle Synopsis
- Telemedicine has become more popular for providing remote healthcare, especially after the COVID-19 pandemic, and may serve as an alternative for routine visits for patients with chronic skin conditions.
- A systematic review of 11 studies (including RCTs) indicates that telemedicine appears to be comparable to in-person consultations for managing chronic inflammatory skin diseases like psoriasis and atopic dermatitis, particularly regarding patient quality of life.
- Despite encouraging results about telemedicine's benefits, such as cost-effectiveness and convenience, further extensive research is needed to solidify these findings and address any uncertainties.
Background And Objective: The most recently approved biologics for moderate-to-severe psoriasis are the interleukin (IL)-17 and IL-23 inhibitors. Drug survival is a frequently used outcome to assess drug performance in practice. An overview of the available drug survival studies regarding IL-17 and IL-23 inhibitors is lacking.
View Article and Find Full Text PDFIntroduction: Psoriasis is a chronic inflammatory condition that can significantly impact the quality of life (QoL), regardless of the level of skin involvement. Apremilast is indicated for the treatment of moderate to severe psoriasis. Real-world data regarding the impact of apremilast on patient-reported outcomes in clinical practice in the Netherlands is lacking.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the impact of psoriasis on patients' work and daily life activities as they start using biological treatments.
- Data from 194 patients showed that after beginning treatment, disease activity significantly decreased, yet work participation remained lower than the general population.
- Although employed patients exhibited improved productivity, nearly half still faced challenges in daily activities, with no significant changes observed over time.
Efficacy and Safety of Tildrakizumab in Older Patients: Pooled Analyses of Two Randomized Phase III Clinical Trials (reSURFACE 1 and reSURFACE 2) Through 244 Weeks.
Acta Derm Venereol
October 2023
The evidence on treating older patients with psoriasis with modern biologics is scarce. This study compared the efficacy and safety of tildrakizumab among younger and older patients with psoriasis (< 65/≥ 65 years) in a post hoc analysis of 2 phase III trials (reSURFACE1/2, n = 1,862). Tildrakizumab 100 mg/200 mg was administered at weeks 0/4/every 12 weeks thereafter.
View Article and Find Full Text PDFGuselkumab induction therapy demonstrates long-lasting efficacy in patients with mild psoriasis, results from a randomized, placebo-controlled exploratory clinical trial.
J Am Acad Dermatol
February 2024
Patients with psoriasis are at risk of developing psoriatic arthritis, which can lead to joint damage. While screening questionnaires have been developed, their performance varies. The objective of this study was to develop a referral tool for dermatologists to identify psoriasis patients with concomitant psoriatic arthritis for rheumatological referral.
View Article and Find Full Text PDFArticle Synopsis
- Anti-drug antibodies (ADA) can form in patients treated with adalimumab (ADL), potentially reducing its effectiveness; using methotrexate (MTX) alongside ADL seems to lower ADA levels and improve outcomes in rheumatologic diseases.
- A study was conducted in the Netherlands and Belgium to compare the long-term effectiveness and safety of ADL combined with MTX versus ADL alone over three years in patients with moderate to severe plaque psoriasis.
- Results showed no significant difference in drug survival between the two groups, even though the ADL + MTX group had a trend towards longer survival; however, adverse events led to common discontinuation in the combination group.
Article Synopsis
- The study examines the risk of SARS-CoV-2 infection in psoriasis patients undergoing different treatments, specifically comparing biologics, systemic conventional therapies, and topical therapies.
- Among 551 patients, only 10.7% were found to have had a SARS-CoV-2 infection, with no significant increase in infection risk for those using biologics.
- The results showed a low hospitalization rate (0.7%) and a mortality rate of 0.32% across all treatment groups, indicating that psoriasis treatment does not significantly affect COVID-19 severity.
Background: Time trend analysis of cutaneous melanoma (CM) mortality in fair skin populations shows both a gradual decrease and/or an increase. To explain these differences, we analyzed long-term time trends in the incidence of the most common histological subtypes of CM: superficial spreading melanoma (SSM), lentigo maligna melanoma (LMM), and nodular melanoma (NM).
Methods: Using data from the Netherlands Cancer Registry and Statistics Netherlands, the number and rates of cases diagnosed with SSM, LLM, and NM from 1989 to 2016 were analyzed by age, calendar period, and birth cohort of people born in successive periods from 1925 to 1973.
Article Synopsis
- Long-term data on the survival of dupilumab in patients with atopic dermatitis (AD) is limited, and there is a need to understand what factors influence its effectiveness over time.
- The study analyzed data from 715 adult patients in the Netherlands, showing that dupilumab had drug survival rates of 90.3%, 85.9%, and 78.6% at 1, 2, and 3 years, respectively.
- Factors linked to shorter drug survival included the use of immunosuppressants and being a nonresponder at 4 weeks, as well as age over 65 and severe forms of AD, indicating specific characteristics that could predict treatment outcomes.
Patients with psoriasis are at risk of developing psoriatic arthritis, which can lead to irreversible joint damage. However, a proportion of patients with psoriasis and concomitant psoriatic arthritis remain undiscovered in practice. The aims of this study were: to prospectively determine prevalence, characteristics, and disease burden of psoriatic arthritis in a psoriasis population; and to determine the prevalence and characteristics of patients with active psoriatic arthritis, who were not under rheumatological care.
View Article and Find Full Text PDFBiologics that block the T helper (Th) 17 pathway are very effective in the treatment of psoriasis and other inflammatory diseases. However, IL-17 is also crucial for antifungal host defense, and clinical trial data suggest an increase in the incidence of Candida infections during IL-17 inhibitor (IL-17i) therapy. We investigated the innate and adaptive immune responses of patients with psoriasis with a history of skin and/or mucosal candidiasis during IL-17i or IL-12/23 inhibitor therapy, comparing those responses with those of healthy controls.
View Article and Find Full Text PDFObjective: To evaluate the effect of lifestyle changes on the severity of psoriasis and the quality of life in patients with psoriasis.
Methods: For this narrative review, PubMed, Embase and ClinicalTrials.gov were searched for lifestyle intervention studies with an intervention duration of at least 12 weeks.
Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort.
Acta Derm Venereol
May 2022
Article Synopsis
- A study was conducted to compare the effectiveness of different biologic therapies for psoriasis, including IL17-inhibitors and TNF-α-inhibitors, using real-world data.
- Researchers analyzed data from 1,080 treatment episodes involving 700 psoriasis patients to assess outcomes like the mean Psoriasis Area and Severity Index (PASI) and how many patients achieved PASI90 or PASI75.
- Results showed that patients on adalimumab, ustekinumab, secukinumab, ixekizumab, and guselkumab had better outcomes than those on etanercept, with ixekizumab and guselkumab leading to even higher rates of achieving PASI90 compared to the other biologics